New progress in adipocytokine research

Current Opinion in Endocrinology and Diabetes

Volumn 10, Issue 2, 2003, Pages 115-121

  Gong, Dawei ^a   Yang, Rongze ^a   Munir, Kashif M ^a   Horenstein, Richard B ^a   Shuldiner, Alan R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Adipocyte; Adipocytokine; Adiponectin; Leptin; Resistin

Indexed keywords

ACYLATION STIMULATING PROTEIN; ADIPONECTIN; ADIPSIN; ANGIOPOIETIN; ANGIOTENSIN; APOLIPOPROTEIN E; ATRIAL NATRIURETIC FACTOR; CHOLESTEROL ESTER TRANSFER PROTEIN; FATTY ACID; INTERLEUKIN 6; LEPTIN; LIPOPROTEIN LIPASE; METALLOTHIONEIN; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTACYCLIN; PROSTAGLANDIN E2; RESISTIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOSE TISSUE; CALORIC INTAKE; CYTOKINE RELEASE; DIABETES MELLITUS; GENOMICS; HUMAN; INSULIN RESISTANCE; LIPOGENESIS; LIPOLYSIS; MOLECULAR BIOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RESEARCH; REVIEW;

EID: 0242475292     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200304000-00004     Document Type: Review

References (77)

1. Zhang Y, Proenca R, Maffei M, et al.: Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432.
2. Must A, Spadano J, Coakley EH, et al.: The disease burden associated with overweight and obesity. JAMA 1999, 282:1523-1529.
3. Matsuzawa Y, Funahashi T, Nakamura T: Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci 1999, 892:146-154.
4. Guerre-Millo M: Adipose tissue hormones. J Endocrinol Invest 2002, 25:855-861.
5. Unger RH, Zhou YT, Orci L: Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc Natl Acad Sci U S A 1999, 96:2327-2332.
6. Considine RV, Sinha MK, Heiman ML, et al.: Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996, 334:292-295.
7. Ahima RS, Prabakaran D, Mantzoros C, et al.: Role of leptin in the neuroendocrine response to fasting. Nature 1996, 382:250-252.
8. Halaas JL, Gajiwala KS, Maffei M, et al.: Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995, 269:543-546.
9. Siegrist-Kaiser CA, Pauli V, Juge-Aubry CE, et al.: Direct effects of leptin on brown and white adipose tissue. J Clin Invest 1997, 100:2858-2864.
10. Kielar D, Clark JS, Ciechanowicz A, et al.: Leptin receptor isoforms expressed in human adipose tissue. Metabolism 1998, 47:844-847.
11. Morton NM, Emilsson V, Liu YL, et al.: Leptin action in intestinal cells. J Biol Chem 1998, 273:26194-26201.
12. Zhang Y, Olbort M, Schwarzer K, et al.: The leptin receptor mediates apparent autocrine regulation of leptin gene expression. Biochem Biophys Res Commun 1997, 240:492-495.
13. Wang J, Liu R, Hawkins M, et al.; A nutrient-sensing pathway regulates leptin gene expression in muscle and fat. Nature 1998, 393:684-688.
14. Zarkesh-Esfahani H, Pockley G, Metcalfe RA, et al.: High-dose leptin activates human leukocytes via receptor expression on monocytes. J Immunol 2001, 167:4593-4599.
15. Sierra-Honigmann MR, Nath AK, Murakami C, et al.: Biological action of leptin as an angiogenic factor. Science 1998, 281:1683-1686.
16. Tartaglia, LA, Dembski M, Weng X, et al.: Identification and expression cloning of a leptin receptor, OB-R. Cell 1995, 83:1263-1271.
17. Chen H, Charlat O, Tartaglia LA, et al.: Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996, 84:491-495.
18. Lee GH, Proenca R, Montez JM, et al.: Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996, 379:632-635.
19. Bjorbaek C, Elmquist JK, Frantz JD, et al.: Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell 1998, 1:619-625.
20. Minokoshi Y, Kim YB, Peroni OD, et al.: Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002, 415:339-343. One of the major biological functions of leptin is to prevent fat accumulation in non-adipose tissues, but the underlying molecular mechanism is not clear. The authors demonstrate that leptin phosphorylates the α2 subunit of AMPK in muscle through two different mechanisms. Early effects are through direct activation while late effects are mediated by the sympathetic nervous system. The AMPK activation leads to the inhibition of ACC activity, which in turn stimulates fat oxidation.
21. Chehab FF, Lim ME, Lu R: Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet 1996, 12:318-320.
22. Cleary MP, Bergstrom HM, Dodge TL, et al.: Restoration of fertility in young obese (Lep(ob) Lep(ob)) male mice with low dose recombinant mouse leptin treatment. Int J Obes Relat Metab Disord 2001, 25:95-97.
23. Chehab FF, Mounzih K, Lu R, et al.: Early onset of reproductive function in normal female mice treated with leptin. Science 1997, 275:88-90.
24. Yura S, Ogawa Y, Sagawa N, et al.: Accelerated puberty and late-onset hypothalamic hypogonadism in female transgenic skinny mice overexpressing leptin. J Clin Invest 2000, 105:749-755.
25. Ahima RS, Dushay J, Flier SN, et al.: Leptin accelerates the onset of puberty in normal female mice. J Clin Invest 1997, 99:391-395.
26. Farooqi IS, Jebb SA, Langmack G, et al.: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999, 341:879-884.
27. Montague CT, Farooqi IS, Whitehead JP, et al.: Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997, 387:903-908.
28. Gruaz NM, Lalaoui M, Pierroz DD, et al.: Chronic administration of leptin into the lateral ventricle induces sexual maturation in severely food-restricted female rats. J Neuroendocrinol 1998, 10:627-633.
29. Ducy P, Amling M, Takeda S, et al.: Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000, 100:197-207.
30. Takeda S, Elefteriou F, Levasseur R, et al.: Leptin regulates bone formation via the sympathetic nervous system. Cell 2002, 111:305-317. This paper elegantly demonstrates that the neural pathway of leptin's anorexigenic effect is separable from its anti-osteogenic function via the sympathetic nervous system, which can be blocked by B-adrenergic antagonism.
31. Hotamisligil GS, Peraldi P, Budavari A, et al.: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996, 271:665-668.
32. Hirosumi J, Tuncman G, Chang L, et al.: A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333-336. This study demonstrates that JNK1 activity is elevated in obese mice and that JNK1 (-/-) mice have decreased adiposity and improved insulin sensitivity. In addition, JNK1 phosphorylates IRS-1 Ser 307, leading to a reduction in insulin signaling. Therefore, JNK1 may be involved in both the development of obesity and obesity-associated insulin resistance.
33. Uysal KT, Wiesbrock SM, Marino MW, et al.: Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389:610-614.
34. Cheung AT, Ree D, Kolls JK, et al.: An in vivo model for elucidation of the mechanism of tumor necrosis factor-alpha (TNF-alpha)-induced insulin resistance: evidence for differential regulation of insulin signaling by TNF-alpha. Endocrinology 1998, 139:4928-4935.
35. Montague CT, Prins JB, Sanders L, et al.: Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes 1998, 47:1384-1391.
36. Kern PA, Saghizadeh M, Ong JM, et al.: The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995, 95:2111-2119.
37. Ofei F, Hurel S, Newkirk J, et al.: Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996, 45:881-885.
38. Scherer PE, Williams S, Fogliano M, et al.: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995, 270:26746-26749.
39. Hu E, Liang P, Spiegelman BM: AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996, 271:10697-10703.
40. Maeda K, Okubo K, Shimomura I, et al.: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996, 221:286-289.
41. Nakano Y, Tobe T, Choi-Miura NH, et al.: Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 1996, 120:803-812.
42. Fruebis J, Tsao TS, Javorshci S, et al.: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Porc Natl Acad Sci U S A 2001, 98:2005-2010.
43. Statnick MA, Beavers LS, Conner LJ, et al.: Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res 2000, 1:81-88.
44. Arita Y, Kihara S, Ouchi N, et al.: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
45. Yamauchi T, Kamon J, Waki H, et al.: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-946.
46. Shapiro L, Scherer PE: The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 1998, 8:335-338.
47. Yamauchi T, Kamon J, Waki H, et al.: Globular adiponectin protected ob/ ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003, 278:2461-2468.
48. Maeda N, Takahashi M, Funahashi T, et al.: PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001, 50:2094-2099.
49. Tomas E, Tsao TS, Saha AK, et al.: Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 2002, 99:16309-16313. This study provides insights into the mechanism of action whereby ACRP30 improves insulin sensitivity and increases fatty acid oxidation. ACRP30 is cleaved into gACRP30 in vivo. Incubation of isolated muscle tissue with gACRPSO, but not the full-length ACRP30, stimulates the phosphorylation of AMPK on Thr-172 and ACC on Ser-79, and diminishes the concentration of malonyl CoA, providing a mechanistic explanation for the increase of fat oxidation by ACRP30.
50. Yamauchi T, Kamon J, Minokoshi Y, et al.: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8:1288-1295. This study demonstrates that both the globular domain and full-length adiponectin raise AMPK levels and activate AMPK, which is required for the metabolic effects of adiponectin, such as ACC phosphorylation, fatty acid oxidation, and glucose uptake in muscle. Interestingly, the authors show that only full-length adiponectin can stimulate activation of hepatocyte AMPK.
51. Maeda N, Shimomura I, Kishida K, et al.: Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8:731-737. Adiponectin KO mice are not different from wild-type mice with respect of body/fat weight, blood levels of glucose, insulin and FFA, and insulin sensitivity on normal chow. However, under high-fat/high-sucrose diet, KO mice exhibit severe insulin resistance associated with a decrease in muscle FATP-1 expression and an increase of adipose TNF-α expression, which can be reversed by viral mediated adiponectin expression in KO mice.
52. Kubota N, Terauchi Y, Yamauchi T, et al.: Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002, 277:25863-25866. This study demonstrates a dose-dependent effect of in vivo adiponectin on insulin sensitivity. Heterozygous adiponectin KO mice (adipo -/+) develop mild insulin resistance while homozygous KO (adipo -/-) mice develop moderate insulin resistance. In addition, adipo -/-mice show increased neo-intimal formation. These studies suggest that adiponectin is protective against insulin resistance and atherosclerosis in vivo.
53. Ma K, Cabrero A, Saha PK, et al.: Increased beta -oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem 2002, 277:34658-34661. This paper reports that adiponectin KO mice are apparently indistinguishable from wild-type mice with respect to body weight, plasma glucose and insulin levels, and glucose and insulin tolerance tests even with a high-fat diet for 7 months. Unexpectedly, adiponectin KO mice exhibit higher fatty acid oxidation than wild-type mice. These results are not in agreement with the findings from references 51 and 52.
54. Kondo H, Shimomura I, Matsukawa Y, et al.: Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 2002, 51:2325-2328.
55. Vasseur F, Helbecque N, Dina C, et al.: Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet 2002, 11:2607-2614.
56. Hara K, Boutin P, Mori Y, et al.: Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 2002, 51:536-540.
57. Steppan CM, Bailey ST, Bhat S, et al.: The hormone resistin links obesity to diabetes. Nature 2001, 409:307-312.
58. Steppan CM, Brown EJ, Wright CM, et al.: A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci U S A 2001, 98:502-506.
59. Rajala MW, Obici S, Scherer PE, et al.: Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 2003, 111:225-230. Using a pancreatic insulin clamp technique, the authors studied the effects of resistin and its homolog RELMb on glucose metabolism and insulin action. They found that these two molecules rapidly induce severe hepatic insulin resistance by increasing liver glucose production, thus providing another piece of experimental evidence that resistin promotes insulin resistance.
60. McTernan CL, McTernan PG, Harte AL, et al.: Resistin, central obesity, and type 2 diabetes. Lancet 2002, 359:46-47.
61. Way JM, Gorgun CZ, Tong Q, et al.: Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator- activated receptor gamma agonists. J Biol Chem 2001, 276:25651-25653.
62. Juan CC, Au LC, Fang VS, et al.: Suppressed gene expression of adipocyte resistin in an insulin-resistant rat model probably by elevated free fatty acids. Biochem Biophys Res Commun 2001, 289:1328-1333.
63. Fasshauer M, Klein J, Neumann S, et al.: Tumor necrosis factor alpha is a negative regulator of resistin gene expression and secretion in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2001, 288:1027-1031.
64. Nagaev I, Smith U: Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001, 285:561-564.
65. Hotamisligil GS: The irresistible biology of resistin. J Clin Invest 2003, 111:173-174.
66. Engert JC, Vohl MC, Williams SM, et al.: 5′ flanking variants of resistin are associated with obesity. Diabetes 2002, 51:1629-1634.
67. Sentinelli F, Romeo S, Arca M, et al.: Human resistin gene, obesity, and type 2 diabetes: mutation analysis and population study. Diabetes 2002, 51:860-862.
68. Osawa H, Onuma H, Murakami A, et al.: Systematic search for single nucleotide polymorphisms in the resistin gene: the absence of evidence for the association of three identified single nucleotide polymorphisms with Japanese type 2 diabetes. Diabetes 2002, 51:863-866.
69. Yoon JC, Chickering TW, Rosen ED, et al.: Peroxisome proliferator- activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol Cell Biol 2000, 20:5343-5349.
70. Kersten S, Mandard S, Tan NS, et al.: Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J Biol Chem 2000, 275:28488-28493.
71. Kim I, Kim HG, Kim H, et al.: Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis. Biochem J 2000, 346:603-610.
72. Yoshida K, Shimizugawa T, Ono M, et al.: Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein li-pase. J Lipid Res 2002, 43:1770-1772. First report on the biological function of ANGPTL4. Like ANGPTL3, intraperitoneal injection of recombinant ANGPTL4 induces hyperlipidemia in mice probably by inhibiting lipoprotein lipase.
73. Shimizugawa T, Ono M, Shimamura M, et al.: ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem 2002, 277:33742-33748.
74. Vgontzas AN, Papanicolaou DA, Bixler EO, et al.: Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab 1997, 82:1313-1316.
75. Bastard JP, Maachi M, Van Nhieu JT, et al.: Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 2002, 87:2084-2089.
76. Fried SK, Bunkin DA, Greenberg AS: Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998, 83:847-850.
77. Wallenius V, Wallenius K, Ahren B, et al.: Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002, 8:75-79. In contrast to the prevailing view that IL-6 plays a pathogenic role in the development of obesity and insulin resistance, this paper shows that mice lacking IL-6 develop mature-onset obesity that can be partially reversed by peripheral IL-6 replacement. In addition, intracerebroventricular IL-6 treatment increases energy expenditure. Therefore, IL-6 appears to be protective against obesity, possibly via its CNS action.